Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 3
1966 1
1967 4
1968 2
1970 3
1971 9
1972 14
1973 18
1974 18
1975 23
1976 22
1977 20
1978 22
1979 14
1980 24
1981 11
1982 18
1983 19
1984 35
1985 28
1986 28
1987 28
1988 30
1989 41
1990 39
1991 40
1992 32
1993 29
1994 48
1995 42
1996 40
1997 35
1998 38
1999 31
2000 36
2001 38
2002 33
2003 53
2004 22
2005 20
2006 22
2007 22
2008 22
2009 16
2010 30
2011 17
2012 18
2013 26
2014 22
2015 14
2016 13
2017 13
2018 18
2019 12
2020 13
2021 6
2022 6
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

1,260 results

Results by year

Filters applied: . Clear all
Page 1
Digoxin and Mortality in Patients With Atrial Fibrillation.
Lopes RD, Rordorf R, De Ferrari GM, Leonardi S, Thomas L, Wojdyla DM, Ridefelt P, Lawrence JH, De Caterina R, Vinereanu D, Hanna M, Flaker G, Al-Khatib SM, Hohnloser SH, Alexander JH, Granger CB, Wallentin L; ARISTOTLE Committees and Investigators. Lopes RD, et al. J Am Coll Cardiol. 2018 Mar 13;71(10):1063-1074. doi: 10.1016/j.jacc.2017.12.060. J Am Coll Cardiol. 2018. PMID: 29519345 Free article. Clinical Trial.
BACKGROUND: Digoxin is widely used in patients with atrial fibrillation (AF). ...However, patients with a serum digoxin concentration 1.2 ng/ml had a 56% increased hazard of mortality (adjusted HR: 1.56; 95% CI: 1.20 to 2.04) compared with those not on digoxin
BACKGROUND: Digoxin is widely used in patients with atrial fibrillation (AF). ...However, patients with a serum digoxin concen …
Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.
Kotecha D, Bunting KV, Gill SK, Mehta S, Stanbury M, Jones JC, Haynes S, Calvert MJ, Deeks JJ, Steeds RP, Strauss VY, Rahimi K, Camm AJ, Griffith M, Lip GYH, Townend JN, Kirchhof P; Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) Team. Kotecha D, et al. JAMA. 2020 Dec 22;324(24):2497-2508. doi: 10.1001/jama.2020.23138. JAMA. 2020. PMID: 33351042 Free PMC article. Clinical Trial.

Adverse events were less common with digoxin; 20 patients (25%) in the digoxin group had at least 1 AE vs 51 patients (64%) in the bisoprolol group (P < .001). There were 29 treatment-related AEs and 16 serious AEs in the digoxin group vs 142 and 37, respe

Adverse events were less common with digoxin; 20 patients (25%) in the digoxin group had at least 1 AE vs 51 patients (64%) in …
The effect of digoxin on mortality and morbidity in patients with heart failure.
Digitalis Investigation Group. Digitalis Investigation Group. N Engl J Med. 1997 Feb 20;336(8):525-33. doi: 10.1056/NEJM199702203360801. N Engl J Med. 1997. PMID: 9036306 Free article. Clinical Trial.
There were 1181 deaths (34.8 percent) with digoxin and 1194 deaths (35.1 percent) with placebo (risk ratio when digoxin was compared with placebo, 0.99; 95 percent confidence interval, 0.91 to 1.07; P=0.80). ...These findings define more precisely the role of dig
There were 1181 deaths (34.8 percent) with digoxin and 1194 deaths (35.1 percent) with placebo (risk ratio when digoxin was co …
Digoxin therapy and associated clinical outcomes in the MADIT-CRT trial.
Lee AY, Kutyifa V, Ruwald MH, McNitt S, Polonsky B, Zareba W, Moss AJ, Ruwald AC. Lee AY, et al. Heart Rhythm. 2015 Sep;12(9):2010-7. doi: 10.1016/j.hrthm.2015.05.016. Epub 2015 May 27. Heart Rhythm. 2015. PMID: 26025322 Clinical Trial.
BACKGROUND: Digoxin's pharmacological, hemodynamic, and electrophysiological properties are well understood. ...No significant differences in digoxin's effect on any of the end points were found between patients with ICD and patients with CRT-D (intera …
BACKGROUND: Digoxin's pharmacological, hemodynamic, and electrophysiological properties are well understood. ...No significant …
Ivabradine for controlling heart rate in permanent atrial fibrillation: A translational clinical trial.
Fontenla A, Tamargo J, Salgado R, López-Gil M, Mejía E, Matía R, Toquero J, Montilla I, Rajjoub EA, García-Fernandez FJ, Miracle A, Rey JR, Bueno H; BRAKE-AF Study Investigators. Fontenla A, et al. Heart Rhythm. 2023 Jun;20(6):822-830. doi: 10.1016/j.hrthm.2023.02.012. Heart Rhythm. 2023. PMID: 37245897 Clinical Trial.
In parallel, a multicenter, randomized, open-label, phase III clinical trial compared ivabradine with digoxin for uncontrolled permanent atrial fibrillation despite beta-blocker or calcium channel blocker treatment. ...Thirty-five (51.5%) patients were randomized to ivabra …
In parallel, a multicenter, randomized, open-label, phase III clinical trial compared ivabradine with digoxin for uncontrolled perman …
Age-related digoxin-alprazolam interaction.
Guven H, Tuncok Y, Guneri S, Cavdar C, Fowler J. Guven H, et al. Clin Pharmacol Ther. 1993 Jul;54(1):42-4. doi: 10.1038/clpt.1993.107. Clin Pharmacol Ther. 1993. PMID: 8330464 Clinical Trial.
A case report of dramatic increases in serum digoxin levels after alprazolam administration prompted our investigation. ...Clinical digoxin toxicity developed in one elderly patient who was receiving 1 mg/day alprazolam....
A case report of dramatic increases in serum digoxin levels after alprazolam administration prompted our investigation. ...Clinical …
Intralesional combined digoxin and furosemide in plantar warts: Does it work?
Fathy G, Abo-Elmagd WM, Afify AA. Fathy G, et al. J Cosmet Dermatol. 2021 Aug;20(8):2606-2611. doi: 10.1111/jocd.13913. Epub 2021 Jan 3. J Cosmet Dermatol. 2021. PMID: 33389796 Clinical Trial.
No treatment has yet proven 100% effective for a cure. DNA viruses rely on K + influx for replication. Both digoxin and furosemide inhibit the K + influx by interacting with cell membrane ion co-transporters. ...The first group received intralesional normal saline and the …
No treatment has yet proven 100% effective for a cure. DNA viruses rely on K + influx for replication. Both digoxin and furosemide in …
A randomized controlled proof-of-concept trial of digoxin and furosemide in adults with cutaneous warts.
Rijsbergen M, Niemeyer-van der Kolk T, Hogendoorn G, Kouwenhoven S, Lemoine C, Klaassen ES, de Koning M, Beck S, Bouwes Bavinck JN, Feiss G, Burggraaf J, Rissmann R. Rijsbergen M, et al. Br J Dermatol. 2019 May;180(5):1058-1068. doi: 10.1111/bjd.17583. Epub 2019 Mar 7. Br J Dermatol. 2019. PMID: 30580460 Free PMC article. Clinical Trial.
BACKGROUND: Topical ionic contraviral therapy (ICVT) with digoxin and furosemide inhibits the potassium influx on which DNA viruses rely for replication. ...Eighty adult patients with at least two cutaneous warts (plantar or common) were randomized to one of four treatment …
BACKGROUND: Topical ionic contraviral therapy (ICVT) with digoxin and furosemide inhibits the potassium influx on which DNA viruses r …
The diltiazem-digoxin interaction.
Rameis H, Magometschnigg D, Ganzinger U. Rameis H, et al. Clin Pharmacol Ther. 1984 Aug;36(2):183-9. doi: 10.1038/clpt.1984.160. Clin Pharmacol Ther. 1984. PMID: 6744777 Clinical Trial.
Diltiazem with digoxin induced an average increase of steady-state plasma digoxin concentration and AUC over 48 hr of 22.4%. ...Apparent volume of distribution was not relevantly altered. Diltiazem kinetics did not change significantly when digoxin was concur …
Diltiazem with digoxin induced an average increase of steady-state plasma digoxin concentration and AUC over 48 hr of 22.4%. . …
Effect of eliglustat on the pharmacokinetics of digoxin, metoprolol, and oral contraceptives and absorption of eliglustat when coadministered with acid-reducing agents.
Thibault N, Ibrahim J, Peterschmitt MJ, Puga AC, Ross L, Vu L, Xue Y, Turpault S. Thibault N, et al. Mol Genet Metab. 2020 Apr;129(4):278-285. doi: 10.1016/j.ymgme.2020.01.001. Epub 2020 Jan 7. Mol Genet Metab. 2020. PMID: 32029355 Free article. Clinical Trial.
Based on in vitro data, clinical trials were conducted to assess the potential for drug-drug interactions between eliglustat and digoxin (P-glycoprotein substrate), metoprolol (sensitive CYP2D6 substrate), a combined oral contraceptive (CYP3A substrate), and acid-reducing …
Based on in vitro data, clinical trials were conducted to assess the potential for drug-drug interactions between eliglustat and digoxin
1,260 results